Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nektar Therapeutics - Common Stock (NQ:NKTR)

66.27 -2.23 (-3.26%)
Streaming Delayed Price Updated: 1:45 PM EDT, Sep 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Nektar Therapeutics - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Nektar (NKTR) Q2 2026 Earnings Call Transcript ↗
Phase 3 trials for rezpegaldesleukin advance in atopic dermatitis and alopecia areata. 
Via The Motley Fool
Topics Earnings
News headline image
Nektar Therapeutics Q2 Earnings Call Highlights ↗
Nektar Therapeutics (NASDAQ:NKTR) said it initiated its global Phase III ZENITH AD program for rezpegaldesleukin, or REZPEG, in moderate-to-severe atopic dermatitis during July, while also finalizing... 
Via MarketBeat
Topics Earnings
News headline image
Full Transcript: Nektar Therapeutics Q2 2026 Earnings Call ↗
Nektar Therapeutics (NASDAQ:NKTR) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For... 
Via Benzinga
NEKTAR THERAPEUTICS (NASDAQ:NKTR) Q1 Earnings Beat Revenue Estimates but EPS Miss Drags Stock Lower ↗
Via Chartmill
Topics Earnings
NEKTAR THERAPEUTICS (NASDAQ:NKTR) Q4 2025 Earnings: Revenue Surges 105% Above Estimates ↗
Via Chartmill
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
What a $1.2 Million Insider Sale Means for Nektar With Shares Up 160% This Past Year ↗
This clinical-stage biopharma focused on oncology and immunology reported a notable insider sale as pipeline programs advance. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch ↗
Biotech firm Nektar Therapeutics advances a pipeline of immunology and oncology candidates through research-driven collaborations. 
Via The Motley Fool
News headline image
This Healthcare Investor Added $43 Million to a Genomics Leader Growing Volume 34% ↗
GeneDx Holdings delivers AI-powered clinical and genomic data analysis for healthcare providers seeking precision medicine solutions. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares ↗
This biotech firm develops immunotherapies for cancer and autoimmune diseases, with several candidates advancing through clinical trials. 
Via The Motley Fool
News headline image
Nektar Therapeutics Q1 Earnings Call Highlights ↗
Nektar Therapeutics (NASDAQ:NKTR) outlined plans to advance its lead regulatory T-cell (Treg) therapy rezpegaldesleukin (REZPEG) into late-stage development, while also reporting first-quarter 2026... 
Via MarketBeat
Topics Earnings
News headline image
Nektar (NKTR) Q1 2026 Earnings Transcript ↗
Nektar (NKTR) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Why Nektar Therapeutics Stock Rocked it Today ↗
The biotech reported solid results from its investigational immunology drug in the treatment of a hair-loss disorder. 
Via The Motley Fool
News headline image
Nektar Therapeutics, Compass Pathways, Sila Realty Trust And Other Big Stocks Moving Higher On Monday ↗
Nektar Therapeutics (NASDAQ: NKTR) rose on positive results for alopecia treatment. Other top gainers include AVEX, CMPS, ATAI, GHRS, POET, SILA, BLD, INV, MXL, KSPI. 
Via Benzinga
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
2 Healthcare Stocks to Buy Before They Get Bought Out ↗
Abivax and Nektar Therapeutics are clinical-stage biotech companies that would make attractive buyout targets. 
Via The Motley Fool
News headline image
Nektar (NKTR) Q4 2025 Earnings Call Transcript ↗
Nektar (NKTR) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
ImmunityBio (IBRX): The Rise of Immunotherapy 2.0 and the Global Expansion of ANKTIVA
As of February 19, 2026, ImmunityBio, Inc. (NASDAQ: IBRX) stands at a pivotal crossroads between clinical ambition and commercial reality. Once a "story stock" fueled by the vision of its billionaire... 
Via Finterra
Topics Lawsuit
Nasdaq, S&P 500 Futures Rise, Markets Await Jobless Claims: Why NVDA, META, NKTR, NVCR, AMAT, ASTS Are On Traders' Radar Today ↗
Via Stocktwits
Topics Stocks
News headline image
NKTR Stock Skyrockets: Wall Street Sees Up To 200% Upside As Skin Trial Crushes Even Bull-Case Forecasts ↗
The company reported that complete skin clearance rates increased twofold to fivefold during the maintenance phase of the trial. 
Via Stocktwits
Top stock movements in today's session. ↗
Via Chartmill
Here are the top movers in Tuesday's session. ↗
Via Chartmill
These stocks are gapping in today's session ↗
Via Chartmill
Top movers in Tuesday's pre-market session ↗
Via Chartmill
News headline image
NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results ↗
Nektar announced positive results from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of its experimental drug, rezpegaldesleukin. 
Via Stocktwits
News headline image
Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead ↗
There is a key difference between these two biotechs. 
Via The Motley Fool
Topics Bankruptcy
News headline image
This Biotech Is Up 194% in a Year but One Investor Took Millions Off the Table ↗
When a biotech rallies nearly 200% and still gets trimmed, the real story likely isn’t about fear or a loss of conviction. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away ↗
ANI is firing on all cylinders operationally, which makes this exit less about fundamentals and more about portfolio discipline at a moment when expectations might be sky-high. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. ↗
Shares in the biotech company have surged on news of a big pharma takeover. 
Via The Motley Fool
News headline image
Nektar Therapeutics (NASDAQ:NKTR) Q3 2025 Earnings Top Estimates, Sending Shares Higher ↗
Nektar Therapeutics (NKTR) Q3 2025 results beat analyst estimates for both revenue and earnings per share, sending the stock higher in after-hours trading. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.